Skip to content

Advertisement

BMC Geriatrics

What do you think about BMC? Take part in

Volume 10 Supplement 1

de Senectute: Age and Health Forum

Open Access

Current perspectives in the management of patients with drug-induced osteonecrosis of the maxilla: experience of the school of Naples Federico II

  • S Ferrara1 and
  • L Califano1
BMC Geriatrics201010(Suppl 1):A56

https://doi.org/10.1186/1471-2318-10-S1-A56

Published: 19 May 2010

Background

Abstract Objective. The use of bisphosphonates (zoledronic acid) in the treatment of metastatic bone disease and osteoporosis has been raised during recent years. The purpose of this treatment is mainly to reduce skeletal-related events, e.g. pain and pathological fractures. Bisphosphonate-related osteonecrosis of the jaw. (BRONJ) adversely affects the quality of life, producing significant morbidity in afflicted patients. BRONJ can develop spontaneously or after minor trauma. In general, these patients seem to have less severe manifestations of necrosis and respond more readily to stage-specific treatment regimens (Table 1). Strategies for the treatment of patients with, or at risk of, BRONJ we reset forth in the American Association of Oral and Maxillofacial Surgeons (AAOMS) Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws (Position Paper) and approved by the Board of Trusteesin September 2006.1This update contains revisions to the diagnosis and staging and management strategie sand highlights the status of basic science research. We to report the incidence of bisphosphonate-related osteonecrosis of the jaw (ONJ), since the initiation of a routine maxillofacial examination before treatment with bisphosphonates, no ONJ has been seen.
Table 1

Staging and treatment strategies

BRONJ* Stage

Description

Treatment Strategies†‡§

At risk category

No apparent necrotic bone in patients who have been treated with either oral or IV bisphosphonates

No treatment indicated Patient education

Stage 0

No clinical evidence of necrotic bone, but nonspecific clinical findings and symptoms

Systemic management, including use of pain medication and antibiotics

Stage 1

Exposed and necrotic bone in asymptomatic patients without evidence of infection

Antibacterial mouth rinse

Clinical follow-up on quarterly basis

Patient education and review of indications for continued bisphosphonate therapy

Stage 2

Exposed and necrotic bone associated with infection as evidenced by pain and erythema in region of exposed bone with or without purulent drainage

Symptomatic treatment with oral antibiotics

Oral antibacterial mouth rinse

Pain control

Superficial debridement to relieve soft tissue irritation

Stage 3

Exposed and necrotic bone in patients with pain, infection, and one or more of the following: exposed and necrotic bone extending beyond the region of alveolar bone, (ie, inferior border and ramus in the mandible, maxillary sinus and zygoma in the maxilla) resulting in pathologic fracture, extraoral fistula, oral antral/oral nasal communication, or osteolysis extending to the inferior border of the mandible or the sinus floor

Antibacterial mouth rinse

Antibiotic therapy and pain control

Surgical debridement/resection for longer term palliation of infection and pain

Abbreviations: BRONJ, bisphosphonate-related osteonecrosis of the jaw; IV, intravenous.

*Exposed bone in maxillofacial region without resolution within 8-12 weeks in persons treated with bisphosphonate who have not undergone radiotherapy to jaws.

†Regardless of disease stage, mobile segments of bony sequestrum should be removed without exposing uninvolved bone;extraction of symptomatic teeth within exposed, necrotic bone should be considered because it is unlikely that extraction will exacerbate established necrotic process.

‡Discontinuation of IV bisphosphonates has shown no short-term benefit. However, if systemic conditions permit,long-term discontinuation might be beneficial in stabilizing established sites of BRONJ, reducing risk of new site development,and reducing clinical symptoms. Risks and benefits of continuing bisphosphonate therapy should be made only by treating oncologist in consultation with oral and maxillofacial surgeon and patient.

§Discontinuation of oral bisphosphonate therapy in patients with BRONJ has been associated with gradual improvement in clinical disease. Discontinuation of oral bisphosphonates for 6-12 months may result in either spontaneous sequestration or resolution after debridement surgery. If systemic conditions permit, modification or cessation of oral bisphosphonate therapy should be done in consultation with treating physician and patient.

Conclusions

ONJ is a rare but a very serious complication in relation to treatment with bisphosphonates. To decrease the incidence of ONJ, a maxillofacial examination could be performed in all patients before treatment with bisphosphonates.

Authors’ Affiliations

(1)
Department of Oral and Maxillofacial Surgery, Federico II University

References

  1. Advisory Task Force on Bisphosphonate-Related Osteonecrosisof the Jaws,: American Association of Oral and MaxillofacialSurgeons position paper on bisphosphonate-related osteonecrosisof the jaws. J Oral Maxillofac Surg. 2009, 67: 2-12.View ArticleGoogle Scholar

Copyright

© Ferrara and Califano; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.

Advertisement